ANDA 77671, held by Watson Laboratories. Amlodipine Besylate.
As of Nov 21, 2026, ANDA 77671 (Amlodipine Besylate), held by Watson Laboratories, was first approved by FDA on Jul 19, 2007, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 19, 2007 | Original application | Approved | None posted |
| Amlodipine BesylateEQ 2.5MG BASE · tablet;oral | Amlodipine Besylate | Discontinued |
| Amlodipine BesylateEQ 5MG BASE · tablet;oral | Amlodipine Besylate | Discontinued |
| Amlodipine BesylateEQ 10MG BASE · tablet;oral | Amlodipine Besylate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters